CTS CORP
No SEC Form 4 filings for $CTS in the last 30 days.
Gabelli-related entities filed a Schedule 13D/A stating they collectively hold 5.75% of CTS Corp (CTS), according to the filing. The document describes the reporting persons’ corporate relationships and investment-advisory roles, and notes CTS is a public company with stock quoted on OTCQX for one parent entity.
CTS (CTS) reported Q2 results with management citing growth in medical, industrial, and aerospace/defense, plus operational improvements and a more profitable sales mix. It noted modest transportation declines and one-time items that boosted EPS. Analysts asked about CEO strategy, R&D recurrence, medical margins, pricing and cost inflation, and transportation outlook. CTS shares were about $65.25 after earnings.
Simply Wall St reports CTS Corporation’s Q2 2026 results: sales of $144.78M and net income of $19.16M. The company raised full-year 2026 sales guidance to $565M to $585M and completed a $21.73M share repurchase totaling 468,772 shares since Nov 2025. The article discusses how these updates may affect CTS’s investment case.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CTS (CTS CORP). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent CTS coverage spans earnings, financial news and market movers.
A 13D/A indicates a significant ownership position by an activist-style investor group, which can raise odds of engagement, governance pressure, or strategic review.
Call Q&A highlights segment mix and margin dynamics, but provides no new numeric guidance or fresh disclosure beyond the earnings narrative.
Higher guidance plus active repurchases strengthens the near-term earnings and capital-return narrative, but transportation and medical cyclicality remains a key risk.
Guidance raise and segment mix shift toward medical and aerospace/defense should support earnings expectations, while transportation remains a tariff/geopolitics risk.
Earnings beat supports a positive read-through for the stock.
alphai scores every news story that mentions CTS with an AI model for sentiment and relevance, and aggregates insider trades from CTS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Gabelli-related entities filed a Schedule 13D/A stating they collectively hold 5.75% of CTS Corp (CTS), according to the filing. The document describes the reporting persons’ corporate relationships and investment-advisory roles, and notes CTS is a public company with stock quoted on OTCQX for one parent entity.
4 min readCTS (CTS) reported Q2 results with management citing growth in medical, industrial, and aerospace/defense, plus operational improvements and a more profitable sales mix. It noted modest transportation declines and one-time items that boosted EPS. Analysts asked about CEO strategy, R&D recurrence, medical margins, pricing and cost inflation, and transportation outlook. CTS shares were about $65.25 after earnings.
4 min readSimply Wall St reports CTS Corporation’s Q2 2026 results: sales of $144.78M and net income of $19.16M. The company raised full-year 2026 sales guidance to $565M to $585M and completed a $21.73M share repurchase totaling 468,772 shares since Nov 2025. The article discusses how these updates may affect CTS’s investment case.
4 min readCTS Corporation reported Q2 2026 gross margin of 41.5% and said diversified end markets now make up 59% of revenue. Medical sales grew 45% YoY, industrial rose 16%, while transportation fell 2%. Full-year 2026 sales guidance was raised to $565-$585 million. Management expects aerospace strength in H2 and cautions on tariffs and precious metal inflation.
6 min readMorgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).
7 min readCTS Corp. (CTS) shares rose about 4% on Tuesday after the company reported higher Q2 profit and raised its FY2026 outlook. Q2 net earnings increased to $19.16M from $18.53M, EPS to $0.66 from $0.62, and net sales to $144.78M from $135.31M. FY26 guidance lifted to $565-$585M sales and $2.55-$2.70 adjusted EPS.
3 min readCTS Corporation (NYSE: CTS) shares rose about 5.8% after the company reported Q2 results that beat expectations and raised full-year guidance. CTS said sales were $144.8 million (+7% YoY) and adjusted EPS was $0.74. It now expects 2026 revenue around $575 million (midpoint) and adjusted EPS of $2.63 (midpoint).
4 min readCTS CORP (CTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cts-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 July 28, 2026 FOR IMMEDIATE RELEASE CTS Announces Second Quarter 2026 Results Strong diversification momentum drives record margins and profitability; 2026 outlook raised Lisle, Ill. - CTS Corporation (NYSE: CTS), a leading gl
3 min readThe article links Middle East tensions to a jump in oil prices, with Brent up about 15% above US$100. It also cites Australia’s June employment gain of 76,300 and unemployment at 4.4%. ASX “runners” include Ceretas Ltd (CTS), up 142% after an $8m IPO for portable ultrasound in Alzheimer’s trials, and Pacgold Ltd (PGO), up 82% after high-grade copper-gold results at White Dam.
6 min readThe article compares Q1 results for TTM Technologies (BHE), CTS (CTS), Coherent (COHR), and Plexus (PLXS). TTM reported $846M revenue (+30.4% YoY) and beat EPS and next-quarter revenue guidance. CTS revenue was $139.2M (+10.7%). Coherent revenue was $1.81B (+20.5%). Plexus revenue was $1.16B (+18.7%).
2 min read
